» Articles » PMID: 38791951

Role of Hypoxia and Rac1 Inhibition in the Metastatic Cascade

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 May 25
PMID 38791951
Authors
Affiliations
Soon will be listed here.
Abstract

The hypoxic condition has a pivotal role in solid tumors and was shown to correlate with the poor outcome of anticancer treatments. Hypoxia contributes to tumor progression and leads to therapy resistance. Two forms of a hypoxic environment might have relevance in tumor mass formation: chronic and cyclic hypoxia. The main regulators of hypoxia are hypoxia-inducible factors, which regulate the cell survival, proliferation, motility, metabolism, pH, extracellular matrix function, inflammatory cells recruitment and angiogenesis. The metastatic process consists of different steps in which hypoxia-inducible factors can play an important role. Rac1, belonging to small G-proteins, is involved in the metastasis process as one of the key molecules of migration, especially in a hypoxic environment. The effect of hypoxia on the tumor phenotype and the signaling pathways which may interfere with tumor progression are already quite well known. Although the role of Rac1, one of the small G-proteins, in hypoxia remains unclear, predominantly, in vitro studies performed so far confirm that Rac1 inhibition may represent a viable direction for tumor therapy.

Citing Articles

The Role of RAC2 and PTTG1 in Cancer Biology.

Rakoczy K, Szymanska N, Stecko J, Kisiel M, Sleziak J, Gajewska-Naryniecka A Cells. 2025; 14(5).

PMID: 40072059 PMC: 11899714. DOI: 10.3390/cells14050330.


Effects of Na1.5 and Rac1 on the Epithelial-Mesenchymal Transition in Breast Cancer.

Zha Z, Ge F, Li N, Zhang S, Wang C, Gong F Cell Biochem Biophys. 2024; .

PMID: 39673684 DOI: 10.1007/s12013-024-01625-x.


RAC1 serves as a prognostic factor and correlated with immune infiltration in liver hepatocellular carcinoma.

Li Y, Gu A, Yang L, Wang Q J Cancer Res Clin Oncol. 2024; 150(9):418.

PMID: 39264423 PMC: 11393158. DOI: 10.1007/s00432-024-05933-w.


The Roles of RAC1 and RAC1B in Colorectal Cancer and Their Potential Contribution to Cetuximab Resistance.

Wahoski C, Singh B Cancers (Basel). 2024; 16(13).

PMID: 39001533 PMC: 11240352. DOI: 10.3390/cancers16132472.

References
1.
Gaustad J, Simonsen T, Acosta Roa A, Rofstad E . Tumors exposed to acute cyclic hypoxia show increased vessel density and delayed blood supply. Microvasc Res. 2012; 85:10-5. DOI: 10.1016/j.mvr.2012.11.002. View

2.
Mittal D, Gubin M, Schreiber R, Smyth M . New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014; 27:16-25. PMC: 4388310. DOI: 10.1016/j.coi.2014.01.004. View

3.
Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

4.
Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

5.
Iden S, Collard J . Crosstalk between small GTPases and polarity proteins in cell polarization. Nat Rev Mol Cell Biol. 2008; 9(11):846-59. DOI: 10.1038/nrm2521. View